DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data

The report comes even as the government considers applications of at least three firms seeking emergency approval to roll out their vaccines against the coronavirus in India

COVID-19 vaccine update: Six vaccines are undergoing trials in the country and are in different phases of development

As many as 341 new fatalities were reported in the past 24 hours, pushing the overall death toll to 1,45,477.  India's COVID-19 case fatality rate is 1.45 per cent, which is one of the lowest in the world

The COVID-19 vaccine in India will be first offered to healthcare workers, frontline workers and persons above 50 years of age. Depending on the disease epidemiology and vaccine's availability, the remaining population will be vaccinated later on

Authorisation by the MHRA will also give confidence to countries across the world. India has already manufactured more than 50 million of the AstraZeneca vaccines, the newspaper notes

Bolsonaro criticised pharmaceutical giant Pfizer. \"In the Pfizer contract it's very clear: 'we're not responsible for any side effects'. If you turn into a crocodile, it's your problem,\" said Bolsonaro

SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen

Despite the rise in cases, India's Covid-19 recoveries have witnessed a steep exponential rise -- from 50,000 in May to over 95 lakh in December. Recoveries are more than 30 times active cases, says  HealthMin

COVID-19 vaccine will be introduced only when the safety is proven. As is true for other vaccines, the common side effects in some individuals could be mild fever, pain, etc. at the site of injection, said the ministry

As of now, the Hyderabad-based manufacturer is in Phase III of its candidate's clinical trials, having over 25,800 volunteers across 18 sites in the country

India to start 5G trials soon; aims to produce 100 cr mobiles, 5 cr laptops by 2025; Restarting stalled mines can help achieve $5 trillion economy target, says metals and mining magnate Anil Agarwal; DCGI seeking more data for authorisation won't impact COVID-19 vaccine roll-out timeline. Watch this and more news on News Blast.

DCGI seeking more data for authorisation won't impact COVID-19 vaccine roll-out timeline: Govt The applications of Bharat Biotech, Serum Institute and Pfizer seeking emergency use authorisation for their COVID-19 vaccines are being examined, the Centre said on Tuesday asserting that drug regulator DCGI seeking more data from these companies will not impact the vaccine-roll out timeline. Infosys has done a terrific job of completely reinventing itself: Nandan NilekaniWith COVID-19 acceler...

The applications are being examined on scientific basis, using the frameworks that are scientific, frameworks that are globally aligned and ensuring that the vaccine is safe, NITI Aayog member (health) Dr V K Paul said

The humongous amounts of data that will be generated during the global vaccination process needs to be analysed almost real-time. That's where an integrated SCM suite embedded with emerging technology comes in

David Prior says next three months are going to be extremely difficult and the world is pinning hopes on vaccine; Serum Institute also hopes to get approval for emergency use in India soon after nod in the UK

The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States

 India readies for 60 crore doses of Covid-19 vaccines to be administered to the most vulnerable people through conventional cold chain systems, says top government expert

US President Donald Trump says: \"We've delivered a safe and effective vaccine in just 9 months. This is one of the greatest scientific accomplishments in history\"

As the country plans to vaccinate 30 crore people by July in the first phase, it may be difficult to bank alone on the Indian vaccines, especially Serum Institute's (SII) Covishield